Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Aug;5(4):323–326. doi: 10.1093/ckj/sfs067

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 1. — Tacrolimus whole blood levels (cross symbols) and clinical findings over time following transplantation. 0 = graft; M = month post-graft; D = days after 1st neurological manifestations; IVIGs=intravenous immunoglobulins. Overall disability sum score (filled circles) was retrospectively calculated according to Merkies ISJ et al., J Neurol Neurosurg Psychiatry, 2002. Tacrolimus whole blood levels were quantified by means of an immunoassay. (A) Variations of tacrolimus levels from M17 to M117 (full line = mean level, dotted lines = highest and lowest levels ever measured). (B) Onset of neurological manifestations at M118 = D0. (C) First neurological impairment at D94. (D) Switch from tacrolimus to sirolimus and beginning of IVIGs at D105. (E) First clinical improvement at D106.